Trial Profile
A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO Grade IV Malignant Glioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2016
Price :
$35
*
At a glance
- Drugs Autologous stem cell therapy (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- 19 Apr 2016 Status changed from active, no longer recruiting to completed.
- 05 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 05 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.